Re-craniotomy and Complications After Elective Neurosurgery

NCT ID: NCT03910556

Last Updated: 2019-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

439 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-31

Study Completion Date

2019-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective cohort study to find the incidence of re-craniotomy and predictive factors. The secondary outcomes are to find the incidence of major non-neurological complications and predictive factors.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Demographic data include age, gender, preoperative neurological assessment, diagnosis, operation, surgical position, ASA physical status, dexamethasone requirement, anticonvulsant therapy, airway assessment, and blood component reservation.

Intraoperative information contain anesthetic technique, total dosage of propofol, fentanyl, and other anesthetic agents, total blood loss, types and amount of fluid replacement, volume of blood transfusion, latest body temperature, and the ability of safe extubation.

Postoperative complications will be categorized in to general conditions, neurological complications, and systemic problems. General conditions such as on endotracheal tube overnight and postoperative blood transfusion. Neurological complications include worsen increased ICP, intracranial hematoma, seizures, newly-developed motor deficit, cranial nerve palsy, CSF rhinorrhea, and emergency re-craniotomy. Systemic problems are hypothermia, electrolyte imbalance, anemia, hypertension, and hyperglycemia. Postoperative nausea and vomiting and the rescued anti-emetic drugs will be recorded. Postoperative anti-epileptic drug (AED) and pain medication will be collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Brain Tumor Brain Metastases Brain Cancer Brain Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

no complication

the patients who did not develop any kind of complication and no re-craniotomy

Propofol

Intervention Type DRUG

intraoperative factors

with complication (s)

the patients who developed at least one of non-neurological complication or required re-craniotomy

Propofol

Intervention Type DRUG

intraoperative factors

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Propofol

intraoperative factors

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

surgical duration operation blood loss blood used fluid volume administration

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who are scheduled for elective craniotomy during 2017-2019
* Patients who are planned for general anesthesia
* Patients have read the study information and signed in the consent form

Exclusion Criteria

* Patients who are unable to understand and sign in the consent form
* Patients who are scheduled for minor surgical procedures such as ventriculostomy and VP-shunt
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yodying Punjasawadwong

UNKNOWN

Sponsor Role collaborator

Prangmalee Leucharussamee

UNKNOWN

Sponsor Role collaborator

Ananchanok Saringkarinkul

UNKNOWN

Sponsor Role collaborator

Patipan Krungsri

UNKNOWN

Sponsor Role collaborator

Chiang Mai University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pathomporn Pin on, M.D.

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pathomporn Pin-on, MD

Role: PRINCIPAL_INVESTIGATOR

Chiang Mai University

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ANE-2561-05961

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.